BLTE Belite Bio Inc.
Health Care, filed as BELITE BIO INC (SPONSORED ADS), Equity As of 2026 Q3 so far: 135 of 140 managers we track have filed Quote on Google Finance, opens in a new tab
In 2026 Q3 Lee Ainslie added to Belite Bio.
Who owns this now
Largest portfolio weights among holders, up to 0.8% (Lee Ainslie, Maverick Capital). Not free-float ownership.
Who owns BLTE
Sorted by value, long equity only, as of 2026 Q3.
| History | |||||
|---|---|---|---|---|---|
| Lee Ainslie, Maverick Capital | Add +53.9% | 609,906 | $104M | History | |
| Stanley Druckenmiller, Duquesne Family Office | Hold | 106,100 | $18M | History |
Insider trades
Open-market buys and sales by BLTE's executives, directors and 10% owners in the last 12 months, from their Form 4s
- None no insider bought on the open market
- $2.9M sold by 1 insider outside a trading plan
- $38.1M sold by 5 insiders under 10b5-1 plans
-
Hendrik Peter Scholl Chief Medical OfficerPlanned sale$332K 2,000 shares at $165.99 14% of stakeTraded Nov 12 Filed Nov 16
-
Hendrik Peter Scholl Chief Medical OfficerPlanned sale$83K 500 shares at $165.32 3.3% of stakeTraded Oct 1 Filed Oct 5
-
Yu-Hsin Lin CEOPlanned sale$19.1M 100,435 shares at $190.00 59% of stakeTraded Sep 4–8 Filed Sep 9
-
Hao-Yuan Chuang CFOPlanned sale$12.8M 67,395 shares at $189.98 72% of stakeTraded Sep 4–8 Filed Sep 9
-
Hao-Yuan Chuang CFOPlanned sale$66K 367 shares at $180.35 0.4% of stakeTraded Aug 12 Filed Aug 14
-
Yu-Hsin Lin CEOPlanned sale$66K 365 shares at $180.35 0.2% of stakeTraded Aug 12 Filed Aug 14
-
Hendrik Peter Scholl Chief Medical OfficerSale$1.5M 10,000 shares at $145.24 40% of stakeTraded Jun 18 Filed Jun 22
-
Hendrik Peter Scholl Chief Medical OfficerSale$1.4M 10,000 shares at $140.57 29% of stakeTraded Jun 16 Filed Jun 17
-
Nathan L. Mata Chief Scientific OfficerPlanned sale$102K 666 shares at $153.21 100% of stakeTraded May 7 Filed May 8
-
Nathan L. Mata Chief Scientific OfficerPlanned sale$154K 1,000 shares at $153.84 60% of stakeTraded May 6 Filed May 7
-
Nathan L. Mata Chief Scientific OfficerPlanned sale$156K 1,000 shares at $155.50 38% of stakeTraded May 5 Filed May 6
-
Nathan L. Mata Chief Scientific OfficerPlanned sale$156K 1,000 shares at $155.64 27% of stakeTraded May 4 Filed May 5
-
Nathan L. Mata Chief Scientific OfficerPlanned sale$156K 1,000 shares at $155.78 21% of stakeTraded May 1 Filed May 4
-
Nathan L. Mata Chief Scientific OfficerPlanned sale$157K 1,000 shares at $156.97 18% of stakeTraded Apr 30 Filed May 1
-
Nathan L. Mata Chief Scientific OfficerPlanned sale$156K 1,000 shares at $155.82 15% of stakeTraded Apr 29 Filed Apr 30
Also filed in the last 12 months, not counted as buying or selling: 4 other transactions and 1 option exercise.
SEC filings
Recent issuer filings from EDGAR, 11 shown.
| Filed | Form | Detail | Links |
|---|---|---|---|
| 6-K | FORM 6-K | Filing Doc | |
| 424B5 | Filing Doc | ||
| 6-K | FORM 6-K | Filing Doc | |
| 6-K | FORM 6-K | Filing Doc | |
| 6-K | FORM 6-K | Filing Doc | |
| 6-K | FORM 6-K | Filing Doc | |
| 6-K | FORM 6-K | Filing Doc | |
| 6-K | FORM 6-K | Filing Doc | |
| 6-K | FORM 6-K | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| 6-K | Filing Doc |
No filings match this filter.
Financials
US-GAAP annual figures, as tagged in Form 10-K
Newly public, no 10-K financials yet. See the 424B5.
Ownership over time
13Fs that reported it each quarter. Click a bar for that quarter’s holders.
Further reading
As an Amazon Associate, FollowTheFilings earns from qualifying purchases.
- How to Read a Financial Report (Tracy & Tracy) View on Amazon
- Financial Statements QuickStudy Laminated Guide View on Amazon